GeneFerm Biotechnology Co., Ltd.

TPEX:1796 Stock Report

Market Cap: NT$2.6b

GeneFerm Biotechnology Past Earnings Performance

Past criteria checks 4/6

GeneFerm Biotechnology ha aumentado sus ingresos a un ritmo medio anual de 62.7%, mientras que la industria Personal Products ha visto aumentar sus ingresos growing a 16.2% anualmente. Los ingresos han crecido growing a un ritmo medio anual de 19.2%. GeneFerm Biotechnology La rentabilidad de los fondos propios de la empresa es de 14.6% y sus márgenes netos son de 16.5%.

Key information

61.5%

Earnings growth rate

58.7%

EPS growth rate

Personal Products Industry Growth13.9%
Revenue growth rate20.1%
Return on equity14.0%
Net Margin15.7%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

GeneFerm Biotechnology (GTSM:1796) Takes On Some Risk With Its Use Of Debt

Apr 16
GeneFerm Biotechnology (GTSM:1796) Takes On Some Risk With Its Use Of Debt

Will GeneFerm Biotechnology (GTSM:1796) Multiply In Value Going Forward?

Mar 12
Will GeneFerm Biotechnology (GTSM:1796) Multiply In Value Going Forward?

Does GeneFerm Biotechnology (GTSM:1796) Have A Healthy Balance Sheet?

Dec 21
Does GeneFerm Biotechnology (GTSM:1796) Have A Healthy Balance Sheet?

Revenue & Expenses Breakdown
Beta

How GeneFerm Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:1796 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2379412510428
30 Sep 2378112910228
30 Jun 2375212010127
31 Mar 236741039725
31 Dec 22634939624
30 Sep 22617939624
30 Jun 22585869424
31 Mar 22552679124
31 Dec 21522579024
30 Sep 21472468723
30 Jun 21431328523
31 Mar 21393228322
31 Dec 2036858222
30 Sep 20360-138222
30 Jun 20348-208322
31 Mar 20344-288523
31 Dec 19328-288422
30 Sep 19340-108624
30 Jun 19341-68524
31 Mar 1934658324
31 Dec 18357108325
30 Sep 1832677924
30 Jun 18332158124
31 Mar 18349258824
31 Dec 17350288923
30 Sep 17377379423
30 Jun 17406489723
31 Mar 17427708922
31 Dec 16453948821
30 Sep 164591058621
30 Jun 164501078318
31 Mar 16405788218
31 Dec 15375547918
30 Sep 15326267318
30 Jun 15278-16618
31 Mar 15250-106418
31 Dec 14223-186218
31 Dec 1322065617

Beneficios de calidad: 1796 tiene ganancias de alta calidad.

Creciente margen de beneficios: 1796Los actuales márgenes de beneficio netos de (16.5%) son superiores a los del año pasado (15.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Tendencia de beneficios: 1796En los últimos 5 años, los beneficios de la empresa han crecido significativamente: 62.7% al año.

Acelerando crecimiento: 1796El crecimiento de los beneficios de la empresa en el último año (37.6%) está por debajo de su media de 5 años (62.7% al año).

Beneficios vs. Industria: 1796 El crecimiento de los beneficios en el último año (33.4%) superó al del sector Personal Products 28.7% .


Return on Equity

Alto ROE: El Retorno sobre el capital de 1796 (14.6%) se considera bajo.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.